Skip to main content

Genitourinary: RMC-6236-401 (EAP)

Trial ID
07573215
Trial Sponsor
Revolution Medicines, Inc.

Study Name: Expanded Access Program to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib